Previous 10 | Next 10 |
2023-07-25 08:20:12 ET FibroGen ( NASDAQ: FGEN ) appoints Thane Wettig as the company’s interim CEO effective as of July 23, 2023. Mr. Wettig has served as FibroGen’s chief commercial officer and a key member of the senior leadership team since June...
Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the appointment of Thane Wettig as the C...
SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023 financial results on Monday, August 7 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to furt...
2023-07-19 08:00:22 ET FibroGen ( NASDAQ: FGEN ) announced Wednesday that the company has greenlighted a restructuring initiative that includes plans to reduce about 32% of its U.S. workforce and save $30M–$35M in annual expenses in the future. "The company would like to ...
2023-07-01 08:46:00 ET On June 26, FibroGen 's (NASDAQ: FGEN) lead program, pamrevlumab, reported poor late-stage clinical trial results for the second time in a month, sending its stock barreling downward to the tune of 80%. Now, shareholders have little hope that the candidate wil...
NEW YORK, NY / ACCESSWIRE / June 30, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN). Investors who purchased FibroGen securities are encouraged to obtain additional information ...
2023-06-27 18:10:17 ET Stifel has downgraded its rating of FibroGen to hold in the wake of a failed Phase 3 clinical trial for the biotech's lead product pamrevlumab in the treatment of idiopathic pulmonary fibrosis, or IPF. Stifel noted that the drug also recently failed a Phase 3 tria...
2023-06-26 15:26:34 ET Summary FibroGen stock has dropped significantly after the failure of its Zephyrus I trial for IPF treatment, leading the company to halt further development in this area. FGEN's future now relies on its pipeline drugs targeting Duchenne muscular dystrophy a...
2023-06-26 12:52:19 ET Gainers: Benitec Biopharma ( BNTC ) +76% . MoonLake Immunotherapeutics ( MLTX ) +68% . Paltalk ( PALT ) +27% . Whole Earth Brands ( FREE ) +26% . Shengfeng Development Limited ( SFWL ) +26% . Belite Bio...
2023-06-26 10:08:32 ET Gainers: MoonLake Immunotherapeutics ( MLTX ) +69% . Chemomab Therapeutics ( CMMB ) +33% . Acelyrin ( SLRN ) +22% . ORIC Pharmaceuticals ( ORIC ) +15% . Losers: Avalo Therapeutics ( AVTX ) -85% . Fi...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...